Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 5
2013 11
2014 23
2015 16
2016 19
2017 26
2018 25
2019 18
2020 25
2021 13
2022 18
2023 26
2024 31
2025 30
2026 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

264 results

Results by year

Filters applied: . Clear all
Page 1
Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis.
Kishi T, Ikuta T, Citrome L, Sakuma K, Hatano M, Hamanaka S, Nishii Y, Iwata N. Kishi T, et al. Transl Psychiatry. 2025 Jun 24;15(1):211. doi: 10.1038/s41398-025-03439-8. Transl Psychiatry. 2025. PMID: 40555730 Free PMC article.
BACKGROUND: In order to appraise the risk-benefit balance of the three available dual orexin receptor antagonists (DORAs; daridorexant, lemborexant, and suvorexant) for the management of adults with insomnia, we conducted a systematic review and random-effect …
BACKGROUND: In order to appraise the risk-benefit balance of the three available dual orexin receptor antagonists (DORAs; daridorexan …
The orexin story and orexin receptor antagonists for the treatment of insomnia.
Muehlan C, Roch C, Vaillant C, Dingemanse J. Muehlan C, et al. J Sleep Res. 2023 Dec;32(6):e13902. doi: 10.1111/jsr.13902. Epub 2023 Apr 22. J Sleep Res. 2023. PMID: 37086045 Review.
Insomnia is associated with an abnormal state of hyperarousal (increased somatic, cognitive, and cortical activation) and orexin has been identified as a key promotor of arousal and vigilance. ...This review provides an overview of the orexin history, the mec …
Insomnia is associated with an abnormal state of hyperarousal (increased somatic, cognitive, and cortical activation) and orexin …
Orexin Receptor Antagonists and Insomnia.
Wu X, Xue T, Chen Z, Wang Z, Chen G. Wu X, et al. Curr Psychiatry Rep. 2022 Oct;24(10):509-521. doi: 10.1007/s11920-022-01357-w. Epub 2022 Aug 16. Curr Psychiatry Rep. 2022. PMID: 35972717 Review.
RECENT FINDINGS: Research on suvorexant in recent years gradually focus on comorbid insomnia, while lemborexant and daridorexant were still being validated in primary insomnia. ...As for selective ORAs, orexin receptor 2 antagonist seltorexant still ha …
RECENT FINDINGS: Research on suvorexant in recent years gradually focus on comorbid insomnia, while lemborexant and daridorexa …
Targeting the Orexin System in the Pharmacological Management of Insomnia and Other Diseases: Suvorexant, Lemborexant, Daridorexant, and Novel Experimental Agents.
Żełabowski K, Petrov W, Wojtysiak K, Ratka Z, Biedka K, Wesołowski M, Fus K, Ślebioda D, Rusinek M, Sterkowicz M, Radzka I, Chłopaś-Konowałek A. Żełabowski K, et al. Int J Mol Sci. 2025 Sep 6;26(17):8700. doi: 10.3390/ijms26178700. Int J Mol Sci. 2025. PMID: 40943625 Free PMC article. Review.
The orexin (hypocretin) system plays a central role in regulating the sleep-wake cycle through two neuropeptides, orexin-A and orexin-B, which act on OX1R and OX2R receptors. ...DORAs function by selectively dampening orexin-driven arousal, ther …
The orexin (hypocretin) system plays a central role in regulating the sleep-wake cycle through two neuropeptides, orexin …
Insomnia Management: A Review and Update.
Shaha DP. Shaha DP. J Fam Pract. 2023 Jul;72(6 Suppl):S31-S36. doi: 10.12788/jfp.0620. J Fam Pract. 2023. PMID: 37549414 Review.
Treating insomnia has been shown to improve outcomes, including reduced risk of developing cardiovascular and mental health disorders. Insomnia is influenced by the brain's regulation of sleep and wake, which are mutually exclusive events. ...
Treating insomnia has been shown to improve outcomes, including reduced risk of developing cardiovascular and mental health disord …
Orexin receptor antagonists in the treatment of insomnia associated with psychiatric disorders: a systematic review.
Kishi T, Koebis M, Sugawara M, Kawatsu Y, Taninaga T, Iwata N. Kishi T, et al. Transl Psychiatry. 2024 Sep 14;14(1):374. doi: 10.1038/s41398-024-03087-4. Transl Psychiatry. 2024. PMID: 39277609 Free PMC article.
Dual orexin receptor antagonists (DORAs) have been investigated as a treatment for chronic insomnia. The objective of this systematic review was to examine evidence for two DORAs, lemborexant and suvorexant, as treatments for insomnia comorbid with a p …
Dual orexin receptor antagonists (DORAs) have been investigated as a treatment for chronic insomnia. The objective of this sys …
Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials.
Herring WJ, Connor KM, Ivgy-May N, Snyder E, Liu K, Snavely DB, Krystal AD, Walsh JK, Benca RM, Rosenberg R, Sangal RB, Budd K, Hutzelmann J, Leibensperger H, Froman S, Lines C, Roth T, Michelson D. Herring WJ, et al. Biol Psychiatry. 2016 Jan 15;79(2):136-48. doi: 10.1016/j.biopsych.2014.10.003. Epub 2014 Oct 23. Biol Psychiatry. 2016. PMID: 25526970 Clinical Trial.
BACKGROUND: Suvorexant is an orexin receptor antagonist for treatment of insomnia. We report results from two pivotal phase 3 trials. ...The results did not suggest the emergence of marked rebound or withdrawal signs or symptoms when suvorexant was dis …
BACKGROUND: Suvorexant is an orexin receptor antagonist for treatment of insomnia. We report results from two pivotal p …
The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
Coleman PJ, Gotter AL, Herring WJ, Winrow CJ, Renger JJ. Coleman PJ, et al. Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:509-533. doi: 10.1146/annurev-pharmtox-010716-104837. Annu Rev Pharmacol Toxicol. 2017. PMID: 27860547 Review.
Dual orexin receptor antagonists (DORAs) block the activity of orexin 1 and 2 receptors to both reduce the threshold to transition into sleep and attenuate orexin-mediated arousal. Among DORAs evaluated clinically, suvorexant has pharmacokinetic …
Dual orexin receptor antagonists (DORAs) block the activity of orexin 1 and 2 receptors to both reduce the threshold to transi …
Dual orexin receptor antagonists for the treatment of insomnia: systematic review and network meta-analysis.
Rocha RB, Bomtempo FF, Nager GB, Cenci GI, Telles JPM. Rocha RB, et al. Arq Neuropsiquiatr. 2023 May;81(5):475-483. doi: 10.1055/s-0043-1768667. Epub 2023 May 31. Arq Neuropsiquiatr. 2023. PMID: 37257468 Free PMC article.
BACKGROUND: Several randomized clinical trials (RCTs) have shown that dual orexin receptor antagonists (DORAs) are effective in the treatment of chronic insomnia. ...CONCLUSION: Our results suggest that DORAs are associated with greater efficacy when compared with p …
BACKGROUND: Several randomized clinical trials (RCTs) have shown that dual orexin receptor antagonists (DORAs) are effective in the t …
Suvorexant, a Novel Dual Orexin Receptor Antagonist, for the Management of Insomnia.
Han AH, Burroughs CR, Falgoust EP, Hasoon J, Hunt G, Kakazu J, Lee T, Kaye AM, Kaye AD, Ganti L. Han AH, et al. Health Psychol Res. 2023 Jan 28;10(5):67898. doi: 10.52965/001c.67898. eCollection 2022. Health Psychol Res. 2023. PMID: 36726477 Free PMC article.
We further discuss Suvorexant's role in targeting insomnia with other comorbidities. RECENT FINDINGS: Insomnia refers to poor quality and/or quantity of sleep. ...While there are existing treatments that target different receptors and pathways of norma …
We further discuss Suvorexant's role in targeting insomnia with other comorbidities. RECENT FINDINGS: Insomnia refers t …
264 results